ENBIO Co., Ltd. (KOSDAQ:352940)
2,025.00
-55.00 (-2.64%)
At close: Aug 24, 2026
ENBIO Revenue
ENBIO had revenue of 10.44B KRW in the quarter ending June 30, 2026, with 22.51% growth. This brings the company's revenue in the last twelve months to 36.18B, up 7.81% year-over-year. In the year 2025, ENBIO had annual revenue of 33.95B, down -4.77%.
Revenue (ttm)
36.18B
Revenue Growth
+7.81%
P/S Ratio
0.61
Revenue / Employee
452.28M
Employees
80
Market Cap
22.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.95B | -1.70B | -4.77% |
| Dec 31, 2024 | 35.65B | 1.63B | 4.79% |
| Dec 31, 2023 | 34.02B | -215.53M | -0.63% |
| Dec 31, 2022 | 34.24B | 773.80M | 2.31% |
| Dec 31, 2021 | 33.47B | -1.10B | -3.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Humax | 388.31B |
| EXA E&C | 205.20B |
| Dasan Solueta | 164.79B |
| OA Co., Ltd. | 104.86B |
| Studio Samick | 90.48B |
| Deep Commerce | 72.78B |
| C&R Research | 62.70B |
| T Scientific | 35.49B |